Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note issued to investors on Saturday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

BTX opened at $2.15 on Friday. The firm has a 50-day moving average price of $2.18 and a 200-day moving average price of $1.81. Brooklyn ImmunoTherapeutics has a twelve month low of $0.17 and a twelve month high of $10.10. The company has a market capitalization of $126.48 million, a price-to-earnings ratio of -0.95 and a beta of 4.61.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Brooklyn ImmunoTherapeutics stock. Renaissance Technologies LLC increased its stake in Brooklyn ImmunoTherapeutics Inc (NYSE:BTX) by 20.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,459,626 shares of the company’s stock after purchasing an additional 243,826 shares during the period. Renaissance Technologies LLC owned approximately 2.48% of Brooklyn ImmunoTherapeutics worth $360,000 as of its most recent SEC filing. 26.00% of the stock is currently owned by hedge funds and other institutional investors.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.